G&A at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s G&A?
- Monte Rosa Therapeutics, Inc. (GLUE) reported G&A of $10.18M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s G&A changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s G&A increased by 16.9% year-over-year, from $8.7M to $10.18M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s G&A?
- Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s G&A has grown at a 23.3% compound annual growth rate (CAGR), from $15.73M to $36.38M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.